Loading...
Market
What will be Longboard Pharmaceuticals' stock price range by the end of Q4 2024?
3
Resolution / Starting Odds
Below $60 • 25%
$60-$70 • 25%
$70-$80 • 25%
Above $80 • 25%
Stock market data from NASDAQ or other financial data providers
Story
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion at $60/Share, 77% Premium
Oct 14, 2024, 12:13 PM
Lundbeck, a Danish pharmaceutical company, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion. The deal values Longboard at $60 per share, representing a 77% premium to its volume-weighted average price. This acquisition is expected to significantly enhance Lundbeck's neuroscience pipeline, particularly in the area of neuro-rare treatments, including a Phase 3 drug for Dravet syndrome. The transaction has been unanimously approved by the boards of both companies and is anticipated to close in the fourth quarter of 2024, pending regulatory approvals. Centerview LLC advised on the deal. Longboard's stock surged by over 50% in pre-market trading following the announcement.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $20 per share • 25%
$20-$24.99 per share • 25%
$25-$29.99 per share • 25%
$30 or above per share • 25%
Below $2 • 25%
$2 to $3 • 25%
$3 to $5 • 25%
Above $5 • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Decrease by less than 20% • 25%
Decrease by 20% or more • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Below $150 • 33%
$150 - $200 • 33%
Above $200 • 33%
Yes • 50%
No • 50%
Significant enhancement in neuroscience pipeline • 25%
Moderate enhancement • 25%
No significant change • 25%
Negative impact • 25%
Below $166 • 33%
$166 to $213 • 33%
Above $213 • 34%